Drug Trial Radar · NCT04259138
Determination of the Optimal Treatment Target in Ulcerative Colitis
Last checked: Nov 19, 2026Latest source record: Sep 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
672
Actual
Start
Feb 18, 2020
Primary completion
Apr 13, 2026
Study completion Apr 13, 2026
Sponsor
- Lead sponsor
- Alimentiv Inc.Academic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Takeda Development Center Americas, Inc.
- First posted
- Feb 6, 2020
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (participant)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Disease activity and response to therapy in ulcerative colitis (UC) can be assessed by a range of endpoints including symptoms, endoscopic mucosal activity, histological disease activity, and biomarkers. This study aims to determine the optimal treatment target, which is a research priority for the management of UC both to inform clinical practice and to help inform regulatory endpoints and targets for drug development. Participants with active UC will be randomized in a 5:4:1 (initially 2:3:5) ratio to 1 of 3 groups, each with a different treatment target. Treatment targets will be defined as: * Group 1: corticosteroid-free symptomatic remission * Group 2: corticosteroid-free endoscopic + symptomatic remission * Group 3: corticosteroid-free histological + endoscopic + symptomatic remission An interim analysis was performed to assess the proportion of subjects that reached their assigned treatment target after 50 subjects in each group had reached the first 32-week assessment. The interim analysis and projections made based on target achievement rates for all subjects included in the interim analysis resulted in a recommendation to adjust the randomization ratio from 2:3:5 to 5:4:1 for Groups 1, 2 and 3 respectively as of May 5th, 2023. This change was necessary in order to complete the study with approximately 100 subjects achieving treatment target within each group.
Conditions
- Colitis, Ulcerative
Interventions
Treatment Algorithm ABiological
Participants who are not on UC treatment at screening (or who have only used topical therapy) will require standard first-line therapy. Either oral 5-ASA and/or immunosuppressive (azathioprine, 6-mercaptopurine, or methotrexate), with optional oral corticosteroid up to a maximum of 30 mg or prednisone or equivalent, will be initiated.
Treatment Algorithm BBiological
Participants who are taking oral 5-ASA, immunosuppressive (azathioprine, 6-mercaptopurine, methotrexate), and/or oral corticosteroid at screening will follow the treatment algorithm. Participants will change to intravenous vedolizumab therapy. Participants will be assessed to determine it remission target is achieved at weeks 16, 32 and 48. If the participant has achieved their treatment target, they will continue that line of therapy. If the participant has not achieved their treatment target, treatment and/or dose escalation will be administered according to the algorithm.
Treatment Algorithm CBiological
Participants who are taking a TNFα antagonist (infliximab, golimumab, or adalimumab), tofacitinib, or ustekinumab therapy at screening will follow the treatment algorithm. Participants will change to intravenous vedolizumab therapy. Participants will be assessed to determine it remission target is achieved at weeks 16, 32 and 48. If the participant has achieved their treatment target, they will continue that line of therapy. If the participant has not achieved their treatment target, treatment and/or dose escalation will be administered according to the algorithm.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Difference in Time to UC-related Complication Between Treatment Target Groups 1 and 3Time frame: From date of treatment target achievement until date of first UC-related complication until end of study (Week 96), whichever came first
Locations
58 sites in 10 countries. Site status is shown where the registry gives one.
St. Joseph Mercy Hospital/Huron Gastroenterology Associates
Ypsilanti, Michigan
Icahn School of Medicine at Mt Sinai Hospital
New York, New York
New York-Presbyterian/Weill Cornell Medical Center
New York, New York
Digestive Health Partners - Asheville Gastroenterology Associate
Asheville, North Carolina
Atrium Health (Carolinas HealthCare)
Charlotte, North Carolina
Gomel Regional Clinical Hospital
Homyel, Homiel, Belarus
Vitebsk Regional Clinical Hospital
Vitebsk, Vitebsk Oblast, Belarus
Imelda Ziekenhuis Bonheiden
Bonheiden, Antwerp, Belgium
University Hospital Ghent
Ghent, East Flanders, Belgium
UZ Leuven - University Hospital Gasthuisberg
Leuven, Flemish Brabant, Belgium
University of Calgary
Calgary, Alberta, Canada
GIRI (GI Research Institute)
Vancouver, British Columbia, Canada
Barrie GI Associates Inc.
Barrie, Ontario, Canada
McMaster University Medical Centre
Hamilton, Ontario, Canada
London Health Sciences Centre - University Campus
London, Ontario, Canada
LHSC - Victoria Hospital
London, Ontario, Canada
ABP Research Services Corp.
Oakville, Ontario, Canada
Taunton Surgical Centre
Oshawa, Ontario, Canada
Toronto Immune and Digestive Health Institute (TIDHI)
Toronto, Ontario, Canada
McGill University Health Centre (MUHC) Montreal General Hospital
Montreal, Quebec, Canada
CH Saint Etienne Hopital Nord
Saint-Priest-en-Jarez, Auvergne-Rhône-Alpes, France
CHU Besançon - Hôpital Jean Minjoz
Besançon, Bourgogne-Franche-Comté, France
CHRU De Nancy - Hopital de Brabois
Vandœuvre-lès-Nancy, Grand Est, France
CHRU de Lille - Hopital Claude Huriez
Lille, Hauts-de-France, France
CHU de Bordeaux - Hopital Haut Leveque - Groupe Hospitalier Sud
Pessac, New Aquitaine, France
CHRU Montpellier - Hopital Saint Eloi
Montpellier, Occitanie, France
Azienda Ospedaliera - Polyclinico Sant'Orsola-Malpighi
Bologna, Emilia-Romagna, Italy
Ospedale San Raffaele S.r.I.
Milan, Milan, Italy
Istituto Clinico Humanitas
Rozzano, Milan, Italy
Azienda Ospedaliera di Padova
Padova, Padua, Italy
Policlinico Universitario Agostino Gemelli
Roma, Rome, Italy
Radboud University Nijmegen Medical Centre
Nijmegen, Gelderland, Netherlands
Catharina Hospital
Eindhoven, North Brabant, Netherlands
ETZ Hospital Tilburg
Tilburg, North Brabant, Netherlands
Amsterdam UMC - Academisch Medisch Centrum
Amsterdam, North Holland, Netherlands
Szpital Miejski Sw. Jana Pawla II w Elblagu
Elblag, Poland
Oddział Gastroenterologiczny SP ZOZ w Łęcznej
Łęczna, Poland
Szpital Uniwersytecki nr 2 im. dr Jana Biziela w Bydgoszcz
Bydgoszcz, Kuyavian-Pomeranian Voivodeship, Poland
GASTROMED - Kopon, Zmudzinski I Wspolnicy Sp.j.
Torun, Kuyavian-Pomeranian Voivodeship, Poland
Gabinet Endoskopii Przewodu Pokarmowego
Krakow, Lesser Poland Voivodeship, Poland
Showing 40 of 58 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.